Loading…
Kleenhanz, LLC was cited for selling unapproved drug products (Kleenhanz® Towelettes topical antiseptic) that claimed to mitigate, prevent, treat, diagnose, or cure COVID-19, in violation of section 505(a) of the FD&C Act. The products were also deemed misbranded under section 502(ee) of the FD&C Act and were marketed to consumers through the company's website and social media platforms with links to retail sellers including Amazon.com. The FDA found that the introduction and delivery of these products into interstate commerce violated sections 301(a) and (d) of the FD&C Act, particularly concerning given the ongoing public health emergency related to COVID-19 at the time.